PMID- 33577046
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20210630
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 25
IP  - 2
DP  - 2021 Jan
TI  - Efficacy and safety of glucokinase activators for type 2 diabetes mellitus 
      therapy: a meta-analysis of double-blind randomized controlled trials.
PG  - 914-922
LID - 24660 [pii]
LID - 10.26355/eurrev_202101_24660 [doi]
AB  - OBJECTIVE: We aimed to assess the efficacy and safety of oral glucokinase 
      activator (GKA) in the treatment of type 2 diabetes mellitus (T2DM). MATERIALS 
      AND METHODS: We searched and collected randomized controlled trials (RCTs) of 
      glucokinase activators in the treatment of T2DM from PubMed, ClinicalTrails, 
      Cochrane Library, Web of Science, and CNKI databases. Revman5.3 software was used 
      to do the meta-analysis, and the Cochrane tool was used to evaluate the risk of 
      bias in the included RCTs. RESULTS: Seven double-blind RTCs were included in the 
      final analysis, with a total of 762 patients. For the efficacy, the meta-analysis 
      found that GKAs lowed the levels of fasting blood glucose (FPG) (mean difference 
      -0.71, 95% CI: -1.11 to -0.31, based on 459 patients from 5 works of literature) 
      and glycated hemoglobin (HbA1c) (mean difference: -0.65%, 95% CI: -0.82 to -0.48, 
      based on 570 patients from 4 works of literature). Subgroup analysis showed GKAs 
      combined with metformin, but not used alone, reduced the levels of FPG. In terms 
      of safety, GKAs did not affect the total rate of adverse events (AEs). GKAs did 
      not affected the risks of diarrhea (RR 1.59, 95% CI: 0.7 to 3.65,  p =0.26), 
      headache (RR 0.96, 95% CI: 0.41-2.21, p =0.60), and nausea (RR 2.23, 95% CI: 
      0.55-9.12,  p =0.24), but they increased the risk of hypoglycemia (RR 1.81, 95% 
      CI: 1.35 to 2.42, p <0.0001, based on 570 patients from 4 literatures). 
      CONCLUSIONS: Oral GKAs combined with metformin has an evident hypoglycemic effect 
      on T2DM, and they seem to be relatively good tolerant. Further clinical studies 
      are still necessary to explore its long-term efficacy and safety.
FAU - Qu, Y
AU  - Qu Y
AD  - College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, 
      Zhejiang, China. caolingyong@163.com.
FAU - Wang, K
AU  - Wang K
FAU - Lin, S
AU  - Lin S
FAU - Cao, L
AU  - Cao L
FAU - Xu, Z
AU  - Xu Z
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
RN  - EC 2.7.1.2 (Glucokinase)
SB  - IM
MH  - Administration, Oral
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Glucokinase/*metabolism
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*pharmacology
MH  - Metformin/administration & dosage/*pharmacology
MH  - Randomized Controlled Trials as Topic
MH  - Software
EDAT- 2021/02/13 06:00
MHDA- 2021/07/01 06:00
CRDT- 2021/02/12 12:13
PHST- 2021/02/12 12:13 [entrez]
PHST- 2021/02/13 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
AID - 24660 [pii]
AID - 10.26355/eurrev_202101_24660 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2021 Jan;25(2):914-922. doi: 
      10.26355/eurrev_202101_24660.